Eliminates AAV payload constraints and promoter silencing, achieving 99% on-target expression.

Background

Gene therapy is a transformative approach for treating genetic, neurological, and metabolic disorders by delivering therapeutic material into patient cells. Viral vectors, particularly adeno-associated viruses (AAVs), are the primary delivery vehicles due to their ability to efficiently transduce target tissues. To ensure the success of these therapies for chronic conditions, there is a critical need for regulatory elements that drive robust, highly specific, and persistent transgene expression. Clinicians require mechanisms that precisely target specific cell types, such as distinct neuronal populations, while maintaining stable therapeutic activity over a patient’s lifetime.

However, current approaches are severely hindered by the limitations of existing gene promoters. A primary obstacle is the strict payload capacity of viral vectors, as AAV capsids are limited to approximately 4.7 kilobases. Traditional promoters are often too large, restricting the size of therapeutic genes that can be packaged. Furthermore, commonly used promoters frequently suffer from epigenetic silencing, where therapeutic expression decays or is repressed within months, rendering them ineffective for lifelong diseases. Additionally, existing promoters often lack sufficient tissue specificity, leading to significant off-target expression in peripheral organs. This imprecision dilutes therapeutic efficacy and increases toxicity risks.

Technology

This gene therapy solution utilizes ultra-compact gene promoters derived from the pseudorabies virus Latency-Associated Promoter 2 (LAP2). The core technology, including variants like the 278-base-pair MiniLAP2, incorporates optimized transcription factor binding sites—such as CREB, CTCF, and NF-Y motifs—alongside specific enhancer sequences. These engineered promoters drive stable, robust transgene expression across viral vectors like adeno-associated viruses (AAVs) and non-viral systems. A key feature is its highly targeted tissue and cell-type specificity, enabling precise pan-neuronal activity or targeted expression in specific glial cells and peripheral organs.

This technology is uniquely differentiated by its ability to overcome critical size constraints and epigenetic silencing. Its ultra-compact footprint significantly increases the available payload capacity within AAV capsids, allowing for the delivery of larger therapeutic genes. Unlike standard promoters that face repression over time, the integration of NF-Y and CTCF motifs facilitates active chromatin remodeling, ensuring durable expression without silencing. Furthermore, the solution offers exceptional precision, demonstrating up to 99% neuronal specificity with negligible off-target expression in the liver. This remarkable reduction in off-target activity minimizes potential toxicity, providing a significantly safer platform for treating chronic conditions.

Benefits

• Increased Payload Capacity: The ultra-compact size of the engineered promoters (e.g., MiniLAP2 at 278 bp) frees up critical space within size-restricted delivery vectors like AAVs, enabling the delivery of larger therapeutic genes or multiple transgenes.
• Long-Term, Stable Expression: The promoters are highly resistant to epigenetic silencing and inactivation, ensuring persistent, durable therapeutic gene expression that is ideal for treating chronic diseases.
• High Tissue and Cell-Type Specificity: Engineered with specific enhancer sequences, the promoters enable highly precise targeting of desired tissues and cell types (such as specific neuronal or glial subtypes) while minimizing unwanted off-target expression.
• Enhanced Transcriptional Activity: The strategic incorporation of transcription factor binding motifs (such as NF-Y and CTCF) significantly boosts gene expression levels through active chromatin remodeling and transcriptional activation.
• Broad Delivery System Compatibility: The promoters are highly versatile and can be seamlessly integrated into a wide variety of viral vectors (including AAVs, lentiviruses, and adenoviruses) as well as non-viral gene delivery platforms.
• Improved Clinical Safety: By drastically reducing off-target expression in peripheral organs like the liver and spinal cord, the promoters help minimize potential immune responses and systemic toxicity.

Applications

• Neurological gene therapy treatments
• AAV vector payload optimization
• Chronic disease gene therapy
• Neurodegenerative disease modeling
• Targeted cell-specific gene delivery

Additional info

These engineered gene promoters, derived from pseudorabies virus Latency-Associated Promoter 2 (LAP2), feature compact designs like the 278 bp MiniLAP2. Optimized with CREB, CTCF, and NF-Y motifs, they maximize AAV vector payload capacity. They drive robust, long-term transgene expression with high cell-type specificity, particularly in neurons, while resisting epigenetic silencing, making them highly effective for viral and non-viral therapeutic gene delivery.